GBT
Global Blood Therapeutics, Inc.
Nasdaq Global Select$66.6
Open: $67.56 High: $67.56 Low: $63.5 Close: $66.52
Range: 2022-08-08 - 2022-08-09
Volume:2,272,072Market: Open
Powered by Finage Stock APIDelayed data
GBT
Global Blood Therapeutics, Inc. 181 OYSTER POINT BLVD https://www.gbt.com
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.- CEO: Ted W. Love
- Employees: 457
- Sector: Healthcare
- Industry: Biotechnology
GBT News
Latest news about the GBT
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal by Reuters at 8/8/22, 11:09 PMView More →- Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ by Reuters at 8/5/22, 4:54 PMView More →
- Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ by Reuters at 8/5/22, 3:41 PMView More →
- U.S. FDA to review use of GBT's blood disorder therapy in children by Reuters at 9/7/21, 3:06 PMView More →